CN114452308B - Probiotics protective agent, and microecological preparation prepared from same and application thereof - Google Patents

Abstract

The invention discloses a probiotics protective agent and a microecological preparation prepared from the same and application thereof, wherein the probiotics protective agent comprises the following components: chrysanthemum powder, bamboo leaf extract, platycodon root powder and mulberry leaf powder. The invention mixes the probiotics with the probiotics protective agent, which can effectively protect the probiotics, improve the survival rate and the planting rate of the probiotics after passing through the stomach and the intestinal canal, improve the preservation time of the probiotics, relieve and eliminate diarrhea, regulate the balance of intestinal microecology, inhibit the proliferation of intestinal harmful bacteria, and reduce the level of inflammatory factors in the body of patients with chronic enteritis.

Description

Probiotics protective agent, and microecological preparation prepared from same and application thereof

Technical Field

The invention relates to a probiotics protective agent, a microecological preparation prepared from the probiotics protective agent and application of the probiotics protective agent.

Background

The intestinal tract is an important site for digestion and absorption by the human body, and is also the largest immune organ of the human body, and researches are conducted on the intestinal tract, namely the second brain of the human body, because of the widely distributed nervous system in the intestinal tract.

Microorganisms in the human intestinal tract help the human to perform various physiological and biochemical functions. It is known that intestinal microorganisms are more than 1000, which account for about 80% of the human microbial mass, and whose mass is only 1.5-2 kg.

In recent years, many researches show that intestinal flora is closely related to the health condition of human body, and the factors of nutrition absorption, metabolism, immunity, gastrointestinal development and the like of a host are closely influenced, and the genotype, age, immune system and the like of the host play an important role in the formation and stabilization of intestinal flora structures. In this case, intestinal microecology is particularly important.

The total length of human intestinal canal is about 9 meters, the surface area exceeds 300m ², the total number of bacteria living in the intestinal canal is about 10 times of the total number of human cells, and the growth and reproduction of bacteria in the gastrointestinal tract, the living metabolism and the stabilization of the whole microorganism environment can all influence the health state of the gastrointestinal tract and even the whole body of the human body.

Studies have shown that dietary structure and nutrient intake are the most important factors in shaping the structure of the intestinal flora, which on the one hand alters the structure of the intestinal flora; on the other hand, the ingredients of the food which are difficult to be absorbed by human body play a nutritional role through the action of intestinal flora. More and more researches show that the probiotics effect of probiotics on human body is widely focused by people, and the main effect is that the probiotics compete with pathogenic bacteria for binding sites and substrates, so that the intestinal flora balance and the intestinal health of the human body are maintained; but also affects the secretion of microorganisms and host metabolites in the intestinal tract, thereby reducing the intestinal environment, providing energy, reducing bacterial translocation, alleviating endotoxemia, etc.

Although many studies of ferments or probiotics have shown that the intestinal flora can be improved to some extent, the proportion of pathogenic microorganisms is reduced. However, most of the existing probiotics lose activity easily in the processes of processing, transportation and storage with a shelf life, are not easy to maintain stable for a long time, or enter human gastrointestinal tracts, and die or die in a large amount after contacting with human internal environments such as gastric acid, bile or digestive juice, and the effect of the probiotics is weakened.

Disclosure of Invention

The present disclosure provides a probiotic protectant comprising chrysanthemum powder, bamboo leaf extract, platycodon root powder and mulberry leaf powder.

In some embodiments, it further comprises phyllanthus emblica powder.

In some embodiments, it further comprises seabuckthorn powder.

In some embodiments, the mass ratio of the chrysanthemum powder, the bamboo leaf extract, the platycodon grandiflorum powder and the mulberry leaf powder is 1-4:1-4.

In some embodiments, the mass ratio relationship of the phyllanthus emblica powder to the chrysanthemum powder, the bamboo leaf extract, the platycodon grandiflorum powder and the mulberry leaf powder is 1-4:1-4.

In some embodiments, the mass ratio relationship of the phyllanthus emblica powder to the chrysanthemum powder, the bamboo leaf extract, the platycodon grandiflorum powder and the mulberry leaf powder is 3:3:2:2:2 or 3:2:3:1:3.

In some embodiments, the mass ratio relationship of the sea buckthorn powder to the phyllanthus emblica powder, the chrysanthemum powder, the bamboo leaf extract, the platycodon grandiflorum powder and the mulberry leaf powder is 1-4:1-4.

In some embodiments, the mass ratio relationship of the sea buckthorn powder to the phyllanthus emblica powder, the chrysanthemum powder, the bamboo leaf extract, the platycodon grandiflorum powder and the mulberry leaf powder is 2:1:1:4:1:1 or 1:1:1:1:1:1:1.

The present disclosure also provides a probiotic formulation comprising a probiotic and a probiotic protectant as described above.

In some embodiments, wherein the probiotic is lactobacillus and/or bifidobacterium.

In some embodiments, wherein the probiotic is one or more selected from the group consisting of: streptococcus thermophilus, lactobacillus buchneri, bifidobacterium longum, lactobacillus paracasei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus fermentum, lactobacillus helveticus, lactobacillus reuteri or bifidobacterium breve.

In some embodiments, the probiotic preparation further comprises a fruit and vegetable ferment, wherein the fruit and vegetable ferment is preferably selected from fruit and vegetable ferment dry powder, fruit and vegetable ferment juice, fruit and vegetable juice concentrate, fruit and vegetable juice puree, fruit and vegetable ferment granule.

In some embodiments, the mass ratio of the probiotics to the probiotic protectant is 1:0.5-100.

In some embodiments, the mass ratio of the dry powder to the probiotic protectant after the probiotic is mixed with the fruit and vegetable fermentation dry powder is 1:0.5-100, and the probiotic activity is greater than 10 ⁶ CFU/g, greater than 10 ⁷ CFU/g, greater than 10 ⁸ CFU/g, greater than 10 ⁹ CFU/g, greater than 10 ¹⁰ CFU/g or greater than 10 ¹¹ CFU/g.

In some embodiments, the probiotic is solid or liquid.

In some embodiments, the use of the microecological formulation in the preparation of a formulation for regulating the microecological balance in the human intestinal tract.

In some embodiments, the modulating the intestinal microecological balance of the human comprises inhibiting proliferation of intestinal harmful bacteria, optionally including shigella, salmonella, clostridium perfringens, pseudomonas aeruginosa, staphylococcus aureus, and the like.

In some embodiments, the modulating the intestinal microecological balance in a human comprises decreasing the level of an inflammatory factor. The inflammatory factors comprise inflammatory factors related to chronic inflammation of intestinal tracts such as IL-1, IL-6, IL-8, IL-12, IL-17, TNFa, CRP and the like.

Detailed Description

A term of

For easier understanding of the present disclosure, certain technical and scientific terms are specifically defined below. Unless defined otherwise herein, all other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

The term "probiotic" as used in this disclosure refers to a class of active microorganisms beneficial to a host by colonizing the human body to alter the flora composition of a part of the host. By regulating the immune function of host mucous membrane and system or regulating the balance of flora in intestinal tract, the effect of promoting nutrient absorption and maintaining intestinal health is achieved, so that single microorganism or mixed microorganism with definite composition beneficial to health is produced. In special pathological conditions, when the proportion of individual probiotics is seriously unbalanced, the probiotics can also become negative influence on the mucosa or immune function of the human body, and even bring about diseases.

The existing probiotics mainly comprise lactobacillus and bifidobacterium, including but not limited to streptococcus thermophilus (Streptococcus thermophilus), lactobacillus buchneri (Lactobacillus buchneri), bifidobacterium longum (Bifidobacterium longum), lactobacillus paracasei (Lactobacillus paracasei), lactobacillus acidophilus (Lactobacillus acidophilus), lactobacillus rhamnosus (Lactobacillus rhamnosus), lactobacillus fermentum (Lactobacillus fermentum), lactobacillus helveticus (Lactobacillus helveticus), lactobacillus reuteri (Lactobacillus reuteri) and bifidobacterium breve (Bifidobacterium breve).

The fruit and vegetable fermented dry powder is dry powder formed by crushing and mixing conventional edible parts, fermenting with saccharomycetes or other probiotics and dewatering. The fruit and vegetable fermented product can be provided in the form of dry powder, and can also exist in the forms of fruit and vegetable fermented particles, fruit and vegetable juice, fruit and vegetable concentrated juice, fruit and vegetable juice and the like. The fruit and vegetable ferment is not a core functional component of the probiotic protectant or the microecological preparation of the disclosure, and is used as a carrier for providing probiotics which can be taken orally, and can also provide certain energy and nutrient substances for the gastrointestinal flora. When the user is the crowd who does not need to increase sugar substances, such as diabetes, the microecological preparation can not contain fruit and vegetable fermentation products.

The fresh fruits and/or vegetables include, but are not limited to, one or more of peach, apple, pear, kiwi, pineapple, lemon, orange, tangerine, orange, lime, coconut, cantaloupe, papaya, tomato, hawthorn, date, wolfberry fruit, longan, litchi, rambutan, passion fruit, loquat, banana, watermelon, strawberry, cranberry, mandarin orange, pomelo, durian, wax apple, pomegranate, mulberry, blueberry, grape, mango, mangosteen, snake fruit, raspberry carrot, spinach, sword bean, cowpea, lettuce, beet, tomato, cucumber, tremella, agaric, cabbage, celery, leek, and the like.

The traditional Chinese medicine extract disclosed by the invention is based on the principle that the physique characteristics of inflammatory reaction are homologous from liver, spleen and kidney in the theory of traditional Chinese medicine, and the effective components in the medicinal and edible Chinese herbal medicines are utilized to adjust the body wet factors on one hand and the microbial balance on the other hand, so that the intestinal beneficial bacteria activity is kept. The traditional Chinese medicine has the effects of regulating intestinal tract wet factors, regulating intestinal tract microecological balance by utilizing probiotics, inhibiting and removing intestinal tract harmful bacteria, removing intestinal tract wet factors and reducing the level of intestinal tract inflammatory factors. The following medicines are selected for compatibility:

flos Chrysanthemi, pungent, sweet and bitter, has effects of dispelling pathogenic wind, clearing heat, suppressing hyperactive liver, improving eyesight, and removing toxic substances.

Fructus phyllanthi, sweet, sour and astringent, cool, enter lung and spleen and stomach meridians, and have the effects of detoxifying and relieving sore throat, clearing heat and promoting fluid production, moistening lung and reducing phlegm.

Bamboo leaves, sweet, pungent and light, cold, enter heart and lung stomach meridians, and have the effects of clearing heat and relieving restlessness, promoting fluid production and promoting urination.

Radix Platycodi, bitter and pungent, has effects of dispersing lung qi, eliminating phlegm, relieving sore throat, expelling pus, and promoting lung qi.

Mulberry leaf, bitter, sweet and cold, enters lung and liver meridians, and has the effects of dispelling wind-heat, calming liver, improving eyesight, clearing lung-heat, moistening dryness, cooling blood and stopping bleeding.

Hippophae rhamnoides, sour and astringent, warm, enter lung, stomach, spleen and heart meridian, and have the effects of strengthening spleen, promoting digestion, relieving cough, eliminating phlegm, promoting blood circulation and removing blood stasis.

The compatibility of medicines is as follows: the intestinal environment is usually damp-heat. Modern people have good diet condition, more animal food intake, more mental labor, sedentary sitting, excessive thinking and the like, and the intestinal environment is more damp-heat. In order to assist in regulating intestinal flora balance, extracts of herba Lophatheri, fructus Phyllanthi, radix Platycodi, fructus Hippophae, flos Chrysanthemi and folium Mori are used for regulating intestinal microecology of human body. Besides being used as a probiotic protective agent, the traditional Chinese medicine composition also participates in the reconciliation of intestinal microbial flora. The bamboo leaves remove dampness; emblic leafflower fruit, platycodon root and sea buckthorn eliminate phlegm; flos Chrysanthemi and folium Mori are used as wind-dispelling herbs, and are used for dispelling pathogenic wind and removing dampness. Meanwhile, the cold-warm balance of a plurality of medicines is taken into consideration, so that a complete formula is formed.

The chrysanthemum powder, the platycodon root powder, the mulberry leaf powder, the sea buckthorn powder, the bamboo leaf extract and the emblic leafflower fruit powder are powder particles obtained by decocting the traditional Chinese medicine decoction pieces with water at 100 ℃ and then ultrasonic drying. Or extracting and preparing by the conventional preparation process of the traditional Chinese medicine granule in the prior art.

The harmful bacteria in intestinal tract refer to bacteria or actinomycetes or fungi which invade the intestinal tract of human body and cause human body diseases. Including but not limited to shigella, salmonella, bacillus perfringens, pseudomonas aeruginosa, staphylococcus aureus, and the like.

"Administration" and "treatment" when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid refers to the contact of an exogenous drug, therapeutic, diagnostic, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid. "administration" and "treatment" may refer to, for example, therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. Treatment of a cell includes contacting a reagent with the cell, and contacting the reagent with a fluid, wherein the fluid is in contact with the cell. "administration" and "treatment" also mean in vitro and ex vivo treatment of, for example, a cell by an agent, diagnosis, binding composition, or by another cell. "treatment" when applied to a human, veterinary or research subject refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.

By "treating" is meant administering to a patient an internal or external therapeutic agent, such as a composition comprising any of the binding compounds of the present disclosure, that has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, the therapeutic agent is administered to a subject patient or population in an amount effective to alleviate one or more symptoms of the disease to induce regression of such symptoms or to inhibit the development of such symptoms to any clinically measurable extent. The amount of therapeutic agent (also referred to as a "therapeutically effective amount") effective to alleviate any particular disease symptom can vary depending on a variety of factors, such as the disease state, age, and weight of the patient, and the ability of the drug to produce a desired therapeutic effect in the patient. Whether a disease symptom has been reduced can be assessed by any clinical test method that a physician or other healthcare professional typically uses to assess the severity or progression of the symptom. While embodiments of the present disclosure (e.g., therapeutic methods or articles of manufacture) may be ineffective in alleviating each target disease symptom, it should be determined according to any statistical test method known in the art, such as Student t-test, chi-square test, U-test according to Mann and Whitney, kruskal-Wallis test (H test), jonckheere-Terpstra test, and Wilcoxon test, that the target disease symptom should be alleviated in a statistically significant number of patients.

The probiotics protective agent provided by the invention can protect probiotics from being tolerant to gastric acid, bile salt and other organism gastrointestinal environments in vivo and in vitro, and increase survival rate and planting rate of the probiotics, so that the probiotics can effectively play the effect of balancing intestinal flora; on the other hand, the medicine composition can play a role in regulating the damp-heat environment of the intestinal tracts of organisms. The probiotics protective agent, probiotics and fruit and vegetable fermentation powder can reduce intestinal inflammatory factors, assist intestinal flora balance and achieve the effects of eliminating diarrhea, constipation and the like.

Second, examples and test cases

The present disclosure is further described below in connection with the examples, which are not intended to limit the scope of the present disclosure. The experimental method without specific conditions in the disclosed embodiments of the invention is generally according to conventional conditions; or according to the conditions recommended by the manufacturer of the raw materials or goods. The reagents of specific origin are not noted and are commercially available conventional reagents.

Example 1 preparation of probiotic protectants

Taking 12g of probiotics protective agent as a unit, weighing 12g of powdered chrysanthemum powder, phyllanthus emblica powder, lophatherum gracile extract, platycodon grandiflorum powder, mulberry leaf powder and/or sea buckthorn powder, and uniformly mixing, wherein the component amounts of specific experimental examples and comparative examples are shown in the table 1.

Table 1 Experimental examples probiotic protectant composition ratio relationship table

Table 1 the probiotic protectants of each experimental or comparative example were sterilized and the pouches were sealed for storage at 4 ℃.

Example 2 accelerated test of Probiotics protectant against Probiotics protection Rate

To verify the storage protection effect of the probiotic protectant on the probiotics, 2g of each example of probiotic protectant is taken and mixed with 5ml of purified water, and then respectively mixed with fruit and vegetable fermented dry powder containing the probiotics, wherein the fruit and vegetable fermented dry powder comprises:

2g of fruit and vegetable fermented dry powder containing bifidobacterium longum (ATCC.55813);

2g of fruit and vegetable fermented dry powder containing streptococcus thermophilus (ATCC.19258);

2g of fruit and vegetable fermented dry powder containing lactobacillus rhamnosus (ATCC.7469);

Or 1g of fruit and vegetable fermented dry powder containing lactobacillus fermentum (ATCC.11739) and 1g of fruit and vegetable fermented dry powder containing lactobacillus helveticus (ATCC 15009).

The probiotic protective agent solution is fully and uniformly mixed with the fruit and vegetable fermentation dry powder containing probiotics respectively, and then the mixture is freeze-dried into dry powder, and the dry powder is stored in a sealing way under the condition of no other miscellaneous bacteria. Placing in a drying incubator at 37 ℃ for 3 months to accelerate the simulation of the environment in which probiotics are stored for a long time. 5 samples were set up for each probiotic, each probiotic sample having an activity of 9.0X10 ⁹ CFU/g or more as determined by activity prior to testing. Finally, the activity protection rate of each experimental example on probiotics = (post-test probiotic activity/pre-test probiotic activity) ×100% was calculated, and the activity protection rate of each probiotic was averaged. The final protection rates of the various probiotics are shown in Table 2.

Table 2 Probiotics Activity protection ratio for each experimental example

Through the accelerated verification test of the probiotics protective agent on the probiotics protective rate, the traditional Chinese medicine extract added in each experimental example has better protective efficiency than glucan under the condition of drying and preservation, and the experimental examples 3-7 have no obvious statistical difference except that the protective rate of the experimental examples 1 and 2 is slightly lower than that of the experimental examples 3-7.

Example 3 Probiotics protectant protection test against probiotics in a simulated gastric acid Environment

In order to verify the protective effect of the probiotic protective agent on probiotics in gastric acid environment, 2g of each example of probiotic protective agent is mixed with 4ml of purified water, then the mixture is fully and uniformly mixed with 2g of fruit and vegetable fermentation dry powder containing lactobacillus paracasei or 2g of bifidobacterium longum respectively, the mixture is added into 20ml of HCl solution with pH of 2.0, and the mixture is placed in a 37 ℃ incubator environment for 2 hours to simulate the activity preservation condition of probiotics in gastric acid environment. 3 samples were set up for each probiotic, each probiotic sample having an activity of 9.0X10 ⁹ CFU/g or more as determined by activity prior to testing. Finally, the activity protection rate of each experimental example for probiotics = (post-test probiotic activity/pre-test probiotic activity) = 100% was calculated and the activity protection rate of each probiotic was averaged. The final protection rates of the various probiotics are shown in Table 3.

TABLE 3 protection rate of probiotic activity under gastric acid simulating conditions for each experimental example

The test of the protective rate of the probiotics protective agent on the probiotics in the simulated gastric acid environment shows that the probiotics protective agent formed by the traditional Chinese medicine extract can resist the influence of gastric acid on the activity of the probiotics more effectively than the glucan.

Example 4 test of the Effect of probiotic protectants on intestinal microecology in a mouse diarrhea model

To verify the protective effect of the probiotic protectant on the probiotics and the regulation of intestinal flora, a mouse diarrhea model is adopted for verification.

Preparing a probiotic and probiotic protectant mixture (i.e., a microecological mixed solution): respectively taking 1g of fruit and vegetable fermentation dry powder containing bifidobacterium longum, 1g of lactobacillus fermentum and 1g of lactobacillus helveticus, mixing with 2g of probiotics protecting agent of each experimental example, adding 10ml of purified water, and fully and uniformly mixing to form a microecological mixed solution.

Referring to Zhao Yanling et al (2009), a diarrhea model of mice was established, diarrhea mice (SPF grade C57BL mice, peking Vitolihua laboratory animal technologies Co., ltd.) were taken, experimental examples 3-7 and comparative examples were set, and a negative control group (without feeding the microecological mixed solution) and a normal control group (without any diarrhea or microecological solution intervention, only providing normal feeding conditions) were set up, 10 animals per group, each half of the animals were fed with Salmonella of about 10 ⁹ cells on the first and second days after model establishment, and under normal diet, each mouse was fed with 0.8 ml/day of the microecological mixed solution of different experimental examples by tube feeding from the third day, and the negative control group was fed with normal saline instead of the microecological mixed solution for 7 days continuously.

Mice were observed daily for activity and fecal character. Mice were sacrificed on day 10 of the experiment, intestinal contents were taken, and negative control groups, if dead within 10 days, were taken, and the content DNA was extracted in time. The relative abundance of the intestinal microorganisms of the mice is detected, and the DNA of the intestinal contents of the mice on the tenth day is extracted according to the instruction book by adopting QIAAMP FAST DNA Stool Mini Kit. The detection of the intestinal microorganism 16S rDNA was carried out by Jin Weizhi Biotechnology Inc., and the relative abundance of the intestinal microorganism was analyzed.

After the model mice are fed by the microecological mixed solution, diarrhea is remarkably improved, 5 mice in a negative control group die before the experiment day 10, 1 mouse in a comparison group die on the experiment day 7, and the other groups do not die. On day 5, the average body weight of the mice in the negative control group was significantly lower than that in each of the experimental group, the comparative example group, and the normal control group.

According to analysis of the relative abundance of the intestinal microorganisms of the mice, the addition of probiotics can obviously inhibit the proliferation of salmonella in the intestinal tract, and the symptom of diarrhea is eliminated through the inhibition of pathogenic bacteria. In each experimental group containing different combination of traditional Chinese medicine extracts, the probiotic protectant can more effectively protect survival and colonization of the probiotic in intestinal tracts of model mice than glucan.

Table 4 table of relative abundance of intestinal microorganisms in mice of each group on day 10 of the experiment

Example 5 Effect study of micro-ecological Mixed solution on eliminating inflammatory factors in patients with chronic enteritis

In order to verify the protection of probiotics in human body and the regulation of the micro-ecological mixed solution in human intestinal inflammatory reaction, the preparation method verifies the inflammatory factor and diarrhea regulation effect of volunteers with chronic enteritis.

15 Volunteers with chronic enteritis and active period were enrolled and the study was conducted after signing informed consent and privacy agreement. Chronic diarrhea was observed in 15 volunteers, and defecation was performed 4-6 times daily. Pale red or pale purple tongue with white and greasy coating, and soft and moist pulse.

Preparing a probiotic and probiotic protectant mixture (i.e., a microecological mixed solution): each dose of the preparation is prepared by mixing 0.5g of fruit and vegetable fermentation dry powder containing bifidobacterium longum, 0.5g of lactobacillus paracasei and 0.5g of lactobacillus helveticus with 15g of probiotics protectant of experimental example 5 or experimental example 7, adding 15ml of warm water (about 45 ℃) and fully and uniformly mixing to form a micro-ecological mixed solution. Of these, 7 volunteers took the microecological mixed solution containing experimental example 5 (experimental example 5 group), and 8 volunteers took the microecological mixed solution containing experimental example 7 (experimental example 7 group).

Each person takes a dose of the microecological mixed solution in the morning and evening every day for 14 days continuously. Inquiring the stool, sleep and hypodynamia of the patient, collecting venous blood on the 0 th day and the 14 th day of taking the microecological mixed solution for the first time, separating serum, and detecting the levels of inflammatory factors such as IL-1, IL-6, IL-8, TNF-alpha, CRP and the like in the serum of the patient.

TABLE 5 comparison of serum inflammatory factor levels (x+ -s) in patients with chronic enteritis

Note that: * P <0.05, # compared to day 0 and group 5, day 14, P <0.05.

After conditioning for 14 days, the diarrhea symptoms of two groups of chronic enteritis patients are effectively relieved, and the number of times of defecation is changed to 1-2 times per day. The experimental example 5 and the experimental example 7 respectively have 5 patients with self-described hypodynamia and 3 patients with self-described sleep quality improvement, and the experimental example 7 has 5 patients with self-described sleep quality improvement.

Although the foregoing invention has been described in some detail by way of example for purposes of clarity of understanding, the description and examples should not be construed as limiting the scope of the disclosure. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.

Claims (6)

1. A probiotic protectant comprising: the preparation method comprises the following steps of decocting chrysanthemum powder, bamboo leaf extract, platycodon grandiflorum powder, mulberry leaf powder and emblic leafflower fruit powder in water at 100 ℃, extracting, and carrying out ultrasonic drying, wherein the mass ratio relationship of the emblic leafflower fruit powder to the chrysanthemum powder, the platycodon grandiflorum powder, the mulberry leaf powder, the bamboo leaf extract and the emblic leafflower fruit powder is one of the following: 1-4:1-4.

2. The probiotic protectant of claim 1, wherein the mass ratio relationship of the phyllanthus emblica powder to the chrysanthemum powder, the bamboo leaf extract, the platycodon grandiflorum powder and the mulberry leaf powder is one of the following: 3:3:2:2:2 or 3:2:3:1:3.

3. The probiotic protectant of claim 1, further comprising: the sea-buckthorn powder comprises chrysanthemum powder, platycodon root powder, mulberry leaf powder, bamboo leaf extract, phyllanthus emblica powder and sea-buckthorn powder, wherein the sea-buckthorn powder is prepared by decocting Chinese medicinal decoction pieces of chrysanthemum, platycodon root, mulberry leaf, bamboo leaf, phyllanthus emblica and sea-buckthorn in water at 100 ℃, extracting the decoction pieces, and carrying out ultrasonic drying to obtain powdery particles, and the mass ratio relationship between the sea-buckthorn powder and the phyllanthus emblica powder is one of the following: 1-4:1-4.

4. The probiotic protectant of claim 3, wherein the mass ratio relationship of the seabuckthorn powder to phyllanthus emblica powder, chrysanthemum powder, bamboo leaf extract, platycodon grandiflorum powder and mulberry leaf powder is one of the following: 2:1:1:4:1:1 or 1:1:1:1:1.

5. A microecological formulation, comprising: a probiotic and a probiotic protectant according to any one of claims 1 to 4, wherein the probiotic is selected from the group consisting of: streptococcus thermophilus, bifidobacterium longum, lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus helveticus and lactobacillus fermentum.

6. Use of a probiotic according to claim 5, wherein said probiotic is for the preparation of a formulation for regulating the microecological balance of the human intestinal tract.